Apoptotic impact on Brugia malayi by sulphonamido-quinoxaline: search for a novel therapeutic rationale

  • Priyanka S. Bhoj
  • Rahul G. Ingle
  • Kalyan Goswami
  • Lingaraj Jena
  • Shailesh Wadher
Original Paper
  • 9 Downloads

Abstract

Human lymphatic filariasis although not fatal but poses serious socioeconomic burden due to associated disability. This is reflected by the huge magnitude of the estimated disability-adjusted life years of about 5.09 million. Therefore, following WHO mandate, our earlier studies on antifilarial drug development revealed the significance of apoptosis. Apoptotic impact has been implicated in anticancer rationale of several drugs. In this study, we explored the antifilarial potential of sulphonamido-quinoxaline compounds, shown to be specific inhibitor for c-Met kinase in human cancer cells. Out of studied compounds, Q4, showing favorable drug-likeness and medicinal chemistry properties on bioinformatics platform along with subsequently recorded lowest IC100 value, was considered as a suitable antifilarial candidate. Significant apoptosis due to mitochondrial involvement was recorded in drug-treated parasite unlike untreated control. In spite of homology between human c-Met kinase and Brugia malayi counterpart, comparative docking result of this compound showed more favorable binding parameters with the parasitic target. The wide gap between IC100 and LD50 values further confirmed the therapeutic safety. We propose sulphonamido-quinoxaline derivative as a lead candidate for antifilarial drug development. Further study is warranted to authenticate parasitic c-Met kinase as a novel therapeutic target reminiscent of anticancer rationale implicating inhibition of proliferation.

Keywords

Quinoxaline Brugia malayi Apoptosis c-Met kinase Lymphatic filariasis 

Notes

Acknowledgements

We would like to extend our tribute to the Late Dr. MVR Reddy, for his active contribution in this work.

Compliance with ethical standards

The animals used for the experimental purpose were approved by the Institutional Animal Ethics Committee (IAEC), MGIMS, Sevagram, Maharashtra, which follows the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) norms. Peripheral blood mononuclear cells (PBMCs; 1 × 106 cells/mL) of healthy human volunteers, of age 25 to 30 with informed consent, were collected and have been performed in accordance with the ethical recommendations of the Institutional Ethical Committee, MGIMS, Sevagram.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Bag S, Tawari NR, Sharma R, Goswami K, Reddy MV, Degani MS (2010) In vitro biological evaluation of biguanides and dihydrotriazines against Brugia malayi and folate reversal studies. Acta Trop 113:48–51CrossRefPubMedGoogle Scholar
  2. Bahekar SP, Hande SV, Agrawal NR, Chandak HS, Bhoj PS, Goswami K, Reddy MV (2016) Sulfonamide chalcones: synthesis and in vitro exploration for therapeutic potential against Brugia malayi. Eur J Med Chem 124:262–269CrossRefPubMedGoogle Scholar
  3. Behm CA, Bendig MM, McCarter JP, Sluder AE (2004) WHO/TDR scientific working group on ‘RNA interference as a means of identifying drug targets for filariasis’ report: 1Google Scholar
  4. Behm CA, Bendig MM, McCarter JP, Sluder AE (2005) RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol 21:97–100CrossRefPubMedGoogle Scholar
  5. Bennuru S, Meng Z, Ribeiro JM, Semnani RT, Ghedin E, Chan K, Lucas DA, Veenstra TD, Nutman TB (2011) Stage-specific proteomic expression patterns of the human filarial parasite Brugia malayi and its endosymbiont Wolbachia. Proc Natl Acad Sci U S A 108:9649–9654CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bhattacharjee J (2016) Mass drugs administration in India—a failure story. Epidemiology: Open Access 6:252Google Scholar
  7. Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, Wyatt PG (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem 3:435–444CrossRefPubMedGoogle Scholar
  8. Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R (2013) Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther 138:333–408CrossRefPubMedPubMedCentralGoogle Scholar
  9. Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717CrossRefPubMedPubMedCentralGoogle Scholar
  10. Ganapaty S, Ramalingam P, BabuRao CH (2008) SAR study: impact of hydrazide hydrazones and sulfonamide side chain on in vitro antimicrobial activity of quinoxaline. Int J Pharmacology Biology 2:13–18Google Scholar
  11. Hanly EK, Darzynkiewicz Z, Tiwari RK (2015) Biguanides and targeted anti-cancer treatments. Genes Cancer 6:82PubMedPubMedCentralGoogle Scholar
  12. Hussain MA, Sitha AK, Swain S, Kadam S, Pati S (2014) Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases Poverty 3:31CrossRefGoogle Scholar
  13. Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. Eur J Med Chem 65:168–186CrossRefPubMedGoogle Scholar
  14. Kinnamon KE, Engle RR, Poon BT, Ellis WY, McCall JW, Dzimianski MT (2000) Anticancer agents suppressive for adult parasites of filariasis in mongolianjirds. Proc Soc Exp Biol Med 224:45–49CrossRefPubMedGoogle Scholar
  15. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485–495CrossRefPubMedGoogle Scholar
  16. McGarry HF, Plant LD, Taylor MJ (2005) Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric oxide synthase and the cyclooxygenase pathway. Filaria J 4:4CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ojha CR, Joshi B, KC KP, Dumre SP, Yogi KK, Bhatta B, Adhikari T, Crowley K, Marasaini BR (2017) Impact of mass drug administration for elimination of lymphatic filariasis in Nepal. PLoS Negl Trop Dis 11:e0005788CrossRefPubMedPubMedCentralGoogle Scholar
  18. Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3(1_suppl):S7–S19Google Scholar
  19. Porter J, Lumb S, Lecomte F, Reuberson J, Foley A, Calmiano M, le Riche K, Edwards H, Delgado J, Franklin RJ, Gascon-Simorte JM (2009) Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase. Bioorganic Med Chem Lett 19:397–400CrossRefGoogle Scholar
  20. Rao UR, Mehta K, Subrahmanyam D, Vickery AC (1991) Brugia malayi and Acanthocheilonema viteae: antifilarial activity of transglutaminase inhibitors in vitro. Antimicrob Agents Chemother 35:2219–2224CrossRefPubMedPubMedCentralGoogle Scholar
  21. Sänger I, Lämmler G, Kimmig P (1981) Filarial infections of Mastomys natalensis and their relevance for experimental chemotherapy. Acta Trop 38:277–288PubMedGoogle Scholar
  22. Singh SK, Goswami K, Sharma RD, Reddy MV, Dash D (2012) Novel microfilaricidal activity of nanosilver. Int J Nanomedicine 7:1023PubMedPubMedCentralGoogle Scholar
  23. Ton TG, Mackenzie C, Molyneux DH (2015) The burden of mental health in lymphatic filariasis. Infectious Diseases Poverty 4:34CrossRefGoogle Scholar
  24. Wei Y, Wang D, Gentile CL, Pagliassotti MJ (2009) Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol Cell Biochem 331:31–40CrossRefPubMedPubMedCentralGoogle Scholar
  25. World Health Organization. Lymphatic filariasis: fact sheet updated on March 2017 http://www.who.int/mediacentre/factsheets/fs102/en/

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of BiochemistryMahatma Gandhi Institute of Medical SciencesWardhaIndia
  2. 2.School of PharmacyS.R.T.M. UniversityNandedIndia

Personalised recommendations